Abstract

While immunoglobulin therapy has been available in healthcare for many years, the issues related to new brands, product availability, costs and safety continue to change. The shortages of the last ten years and concerns over the transmission of Hepatitis and/or HIV have been replaced with other equally complex and challenging concerns to both patients and clinicians. This article examines the most urgent of those concerns and describes the relevance these issues have to clinical practice.

This content is only available as a PDF.
You do not currently have access to this content.